Skip to main content

Advertisement

SpringerLink
Log in

IMP3 Is a Novel Prognostic Marker that Correlates with Colon Cancer Progression and Pathogenesis

  • Translational Research and Biomarkers
  • Published:
Annals of Surgical Oncology Aims and scope Submit manuscript

Abstract

Background

Insulin-like growth factor-II mRNA-binding protein 3 (IMP3) plays a vital role in carcinogenesis; however, its significance and prognostic value in colon cancer remain unclear.

Methods

In this study, a tissue microarray (TMA) containing 203 samples of primary colon cancer was assessed for IMP3 expression by immunohistochemistry. The TMA included 66 lymph node metastasis (LNM) samples. The mRNA and protein expression levels of IMP3 were evaluated by reverse transcription-PCR and Western blot analysis, respectively.

Results

Cytoplasmic immunoreactivity of IMP3 was significantly higher in LNM (93%) than in primary colon cancer (65%) or normal mucosa (3.9%). Increased IMP3 levels were significantly correlated with higher clinical stage, T classification, LNM, presence of distant metastasis, and Ki-67 positivity. IMP3 was up-regulated in colon cancer compared with paired normal colonic mucosa. IMP3 expression was associated with an 11-fold increased risk of distant metastases (hazard ratio (HR) 10.7; 95% confidence interval (CI) 3.3–34.5; P < 0.0001). Patients with IMP3-positive localized tumors had lower 5-year disease-free survival (DFS) (HR 2.87; 95% CI 1.65–4.98; P < 0.0001) and overall survival (OS) (HR 4.2; 95% CI 2.51–10.17; P < 0.0001) than those with IMP3-negative tumors. Multivariate survival analysis showed that IMP3 was an independent prognostic marker for DFS (HR 1.92; 95% CI 1.06–3.47; P = 0.03) and OS (HR 2.37; 95% CI 1.2–4.7; P = 0.014).

Conclusions

IMP3 may play an important role in colon cancer progression and could serve as a prognostic biomarker to identify patients at risk of developing metastasis or recurrence after colonectomy.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3

Similar content being viewed by others

References

  1. Baker SJ, Fearon ER, Nigro JM, et al. Chromosome 1 deletions and p53 gene mutations in colorectal carcinomas. Science. 1989;244:217–21.

    Article  CAS  PubMed  Google Scholar 

  2. Morin PJ, Sparks AB, Korinek V, Barker N, Clevers H, Vogelstein B, Kinzler KW. Activation of beta-catenin-Tcf signaling in colon cancer by mutations in beta-catenin or APC. Science. 1997;275:1787–90.

    Article  CAS  PubMed  Google Scholar 

  3. Forrester K, Almoguera C, Han K, Grizzle WE, Perucho M. Detection of high incidence of K-ras oncogenes during human colon tumorigenesis. Nature. 1987;327:298–303.

    Article  CAS  PubMed  Google Scholar 

  4. Fan J, Peng Z, Zhou C, et al. Gene-expression profiling in Chinese patients with colon cancer by coupling experimental and bioinformatic genomewide gene-expression analyses: identification and validation of IFITM3 as a biomarker of early colon carcinogenesis. Cancer. 2008;113:266–75.

    Article  CAS  PubMed  Google Scholar 

  5. Nielsen J, Christiansen J, Lykke-Andersen J, Johnsen AH, Wewer UM, Nielsen FC. A family of insulin-like growth factor II mRNA-binding proteins represses translation in late development. Mol Cell Biol. 1999;19:1262–70.

    CAS  PubMed  Google Scholar 

  6. Gress TM, Mueller-Pillasch F, Geng M, et al. A pancreatic cancer-specific expression profile. Oncogene. 1996;13:1819–30.

    CAS  PubMed  Google Scholar 

  7. Runge S, Nielsen FC, Nielsen J, Lykke-Andersen J, Wewer UM, Christiansen J. H19 RNA binds four molecules of insulin-like growth factor II mRNA binding protein. J Biol Chem. 2000;275:29562–9.

    Article  CAS  PubMed  Google Scholar 

  8. Doyle GA, Betz NA, Leeds PF, Fleisig AJ, Prokipcak RD, Ross J. The c-myc coding region determinant-binding protein: a member of a family of KH domain RNA-binding proteins. Nucleic Acids Res. 1998;26:5036–44.

    Article  CAS  PubMed  Google Scholar 

  9. Liao B, Hu Y, Herrick DJ, Brewer G. The RNA-binding protein IMP-3 is a translational activator of insulin-like growth factor II leader-3 mRNA during proliferation of human K562 leukemia cells. J Biol Chem. 2005;280:18517–24.

    Article  CAS  PubMed  Google Scholar 

  10. Mueller-Pillasch F, Pohl B, Wilda M, et al. Expression of the highly conserved RNA binding protein KOC in embryogenesis. Mech Dev. 1999;88:95–9.

    Article  CAS  PubMed  Google Scholar 

  11. Yaniv K, Yisraeli JK. The involvement of a conserved family of RNA binding proteins in embryonic development and carcinogenesis. Gene. 2002;287:49–54.

    Article  CAS  PubMed  Google Scholar 

  12. Hammer NA, Hansen TO, Byskov AG, et al. Expression of IGF-II mRNA-binding proteins (IMPs) in gonads and testicular cancer. Reproduction. 2005;130:203–12.

    Article  CAS  PubMed  Google Scholar 

  13. Simon R, Bourne PA, Yang Q, Spaulding BO, di Sant’Agnese PA, Wang HL, Xu H. Extrapulmonary small cell carcinomas express K homology domain containing protein overexpressed in cancer, but carcinoid tumors do not. Hum Pathol. 2007;38:1178–83.

    Article  CAS  PubMed  Google Scholar 

  14. Gu L, Shigemasa K, Ohama K. Increased expression of IGF II Increased expression of IGF II mRNA-binding protein 1 mRNA is associated with an advanced clinical stage and poor prognosis in patients with ovarian cancer. Int J Oncol. 2004;24:671–8.

    CAS  PubMed  Google Scholar 

  15. Yantiss RK, Woda BA, Fanger GR, et al. KOC (K homology domain containing protein overexpressed in cancer): a novel molecular marker that distinguishes between benign and malignant lesions of the pancreas. Am J Surg Pathol. 2005;29:188–95.

    Article  PubMed  Google Scholar 

  16. Sojka KM, Spaulding BS, Nielsen GK, Dinnogen SA, Welcher R. Immunoreactivity of anti-L523S on normal and malignant lung pleural tissue biopsies. Mod Pathol. 2006;18:288A.

    Google Scholar 

  17. Xu H, Bourne PA, Spaulding BO, Wang HL. High-grade neuroendocrine carcinomas of the lung express K homology domain containing protein overexpressed in cancer but carcinoid tumors do not. Hum Pathol. 2007;38:555–63.

    Article  CAS  PubMed  Google Scholar 

  18. Jiang Z, Chu PG, Woda BA, et al. Analysis of RNA-binding protein IMP3 to predict metastasis and prognosis of renal cell carcinoma: a retrospective study. Lancet Oncol. 2006;7:556–64.

    Article  CAS  PubMed  Google Scholar 

  19. Istvanic S, Fanger GR, Fraire AE, et al. Spectrum of KOC (K homology domain containing protein over-expressed in cancer) immunostaining among carcinomas of different sites. Mod Pathol. 2005;18:298A–9A.

    Google Scholar 

  20. Pryor JG, Bourne PA, Yang Q, Spaulding BO, Scott GA, Xu H. IMP-3 is a novel progression marker in malignant melanoma. Mod Pathol. 2008;21:431–7.

    Article  CAS  PubMed  Google Scholar 

  21. Zheng W, Yi X, Fadare O, Liang SX, Martel M, Schwartz PE, Jiang Z. The oncofetal protein IMP3 A novel biomarker for endometrial serous carcinoma. Am J Surg Pathol. 2008;32:304–15.

    Article  PubMed  Google Scholar 

  22. Hoffmann NE, Sheinin Y, Lohse CM, Parker AS, Leibovich BC, Jiang Z, Kwon ED. External validation of IMP3 expression as an independent prognostic marker for metastatic progression and death for patients with clear cell renal cell carcinoma. Cancer. 2008;112:1471–9.

    Article  PubMed  Google Scholar 

  23. Mueller F, Bommer M, Lacher U, et al. KOC is a novel molecular indicator of malignancy. Br J Cancer. 2003;88:699–701.

    Article  CAS  PubMed  Google Scholar 

  24. O’Connell JB, Maggard MA, Ko CY. Colon cancer survival rates with the new American Joint Committee on Cancer sixth edition staging. J Natl Cancer Inst. 2004;96:1420–5.

    Article  PubMed  Google Scholar 

  25. Zhuang PY, Zhang JB, Zhu XD, et al. Two pathologic types of hepatocellular carcinoma with lymph node metastasis with distinct prognosis on the basis of CK19 expression in tumor. Cancer. 2008;112:2740–8.

    Article  PubMed  Google Scholar 

  26. Hansen TV, Hammer NA, Nielsen J, et al. Dwarfism and impaired gut development in insulin-like growth factor II mRNA-binding protein 1-deficient mice. Mol Cell Biol. 2004;24:4448–64.

    Article  CAS  PubMed  Google Scholar 

  27. Hanley KZ, Facik MS, Bourne PA, Yang Q, Spaulding BO, Bonfiglio TA, Xu H. Utility of anti-L523S antibody in the diagnosis of benign and malignant serous effusions. Cancer. 2008;114:49–56.

    Article  CAS  PubMed  Google Scholar 

  28. Ma C, Rong Y, Radiloff DR, et al. Extracellular matrix protein betaig-h3/TGFBI promotes metastasis of colon cancer by enhancing cell extravasation. Genes Dev. 2008;22:308–21.

    Article  PubMed  CAS  Google Scholar 

  29. Vikesaa J, Hansen TV, Jønson L, Borup R, Wewer UM, Christiansen J, Nielsen FC. RNA-binding IMPs promote cell adhesion and invadopodia formation. Embo J. 2006;25:1456–68.

    Article  CAS  PubMed  Google Scholar 

  30. Li L, Xu H, Spaulding BO, et al. Expression of RNA-binding protein IMP3 (KOC) in benign urothelium and urothelial tumors. Hum Pathol. 2008;39:1205–11.

    Article  CAS  PubMed  Google Scholar 

  31. Sitnikova L, Mendese G, Liu Q, et al. IMP3 predicts aggressive superficial urothelial carcinoma of the bladder. Clin Cancer Res. 2008;14:1701–6.

    Article  CAS  PubMed  Google Scholar 

Download references

Acknowledgment

This study was supported by the fund: the National High Technology Research and Development Program (“863”Program) of China (2007AA022003); Key Basic Research Project of the Science and Technology Commission of Shanghai Municipality (Grant number: 05JC1402); Outstanding Medical Academic Leader of Shanghai Municipality (Grant number: LJ06024).

Author information

Authors and Affiliations

  1. Department of General Surgery, Shanghai Jiaotong University Affiliated First People’s Hospital, Shanghai, People’s Republic of China

    Dawei Li MD, PhD, Dongwang Yan MD, PhD, Chongzhi Zhou MD, PhD, Junwei Fan MD, PhD, Xiaoliang Wang MD, PhD, Jun Xia MD, PhD, Fei Huang MD, Guoqiang Qiu MD & Zhihai Peng MD, PhD

  2. Department of Pathology, Shanghai Jiaotong University Affiliated First People’s Hospital, Shanghai, People’s Republic of China

    Huamei Tang MD & Shuxia Li MD, PhD

  3. Key Laboratory of Molecular Medicine, Shanghai Jiaotong University Affiliated First People’s Hospital, Shanghai, People’s Republic of China

    Shuxia Li MD, PhD

Authors
  1. Dawei Li MD, PhD
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Dongwang Yan MD, PhD
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Huamei Tang MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Chongzhi Zhou MD, PhD
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Junwei Fan MD, PhD
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Shuxia Li MD, PhD
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Xiaoliang Wang MD, PhD
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Jun Xia MD, PhD
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. Fei Huang MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  10. Guoqiang Qiu MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  11. Zhihai Peng MD, PhD
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding authors

Correspondence to Huamei Tang MD or Zhihai Peng MD, PhD.

Additional information

Dawei Li and Dongwang Yan have contributed equally to this work.

Electronic supplementary material

Below is the link to the electronic supplementary material.

Supplementary material 1 (DOC 32 kb)

Rights and permissions

Reprints and permissions

About this article

Cite this article

Li, D., Yan, D., Tang, H. et al. IMP3 Is a Novel Prognostic Marker that Correlates with Colon Cancer Progression and Pathogenesis. Ann Surg Oncol 16, 3499–3506 (2009). https://doi.org/10.1245/s10434-009-0648-5

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1245/s10434-009-0648-5

Keywords

Search

Navigation